Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai Yarkoni with a vision of enabling regenerative medicine to become reality. Realizing that stem cells are one of the pillars of the 21st century medicine, first development was around enabling the mass enrichment of stem cells as a raw material for any and all regenerative treatments. Without such technologies, stem cells based treatments will remain within the confines of laboratories and clinical trials. For regenerative medicine to become publicly available for all people, quality stem cells need to become a commodity, easily available in mass for all medicinal purposes. Cellect was driven by its wish to become the main provider of technologies for pharma companies and medical centers that will make the production of stem cells based products a trivial, safe and inexpensive process. Source
No articles found.
BioCurity is a clinical stage biopharmaceutical company with a mission to material...
BioCurity is a clinical stage biopharmaceutical...
Magellan Health, Inc., a Fortune 500 company, is a leader in managing the fastest ...
Magellan Health, Inc., a Fortune 500 company, i...
Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to address...
Foamix Pharmaceuticals is a specialty pharmaceu...
InnaMed is developing a comprehensive care management platform. Our team is develo...
InnaMed is developing a comprehensive care mana...
CAVU Biotherapies offers a comprehensive solution to prepare for, monitor, and tre...
CAVU Biotherapies offers a comprehensive soluti...
We make affordable assistive products, starting with a groundbreaking supportive w...
We make affordable assistive products, starting...
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials compa...
PolarityTE is a commercial-stage biotechnology ...
MiMedxŽ is a biopharmaceutical company developing, manufacturing and marketing reg...
MiMedxŽ is a biopharmaceutical company developi...
Join the National Investor Network and get the latest information with your interests in mind.